EGFR在三阴性乳腺癌中的作用及靶向治疗研究进展被引量：4

Research advances in the roles of EGFR and targeted therapy in triple negative breast cancer

导出

摘要 2022年,乳腺癌在全球恶性肿瘤中位居发病率首位,并且其复发率和致死率较高,严重威胁着人类的生命健康。三阴性乳腺癌(triple negative breast cancer,TNBC)是乳腺癌中预后最差的类型,常伴随着表皮生长因子受体(epidermal growth factor receptor,EGFR)的高表达。EGFR广泛分布于各种细胞表面,其介导的信号通路主要参与细胞生长、增殖和分化等过程。EGFR过表达常与肿瘤的侵袭、转移、浸润和患者预后有着密切的关系。因此,阐明EGFR在TNBC中的作用机理以及研究相应的防治策略,有助于预防和控制乳腺癌的发生,提高患者的生活质量。本文对EGFR在TNBC中的作用机制、治疗策略及耐药的主要研究进展做一综述,以期为乳腺癌的治疗和预后的改善提供更多参考。 In 2022,breast cancer ranks the first in incidence among all malignant tumors worldwide,and it’s high recurrence and fatality rate has posed serious threat to human life and health.Triple negative breast cancer(TNBC)is known for its poor prognosis among all types of breast cancer,and is often associated with elevated expression of epidermal growth factor receptor(EGFR).EGFR is widely expressed on the surface of various cells.The signaling pathway mediated by EGFR is mainly involved in cell growth,proliferation and differentiation.EGFR overexpression is often closely related to tumor invasion,metastasis and prognosis.Therefore,elucidating the roles of EGFR in TNBC and developing prevention and treatment strategies correspondingly are helpful to prevent and control the occurrence of breast cancer,and improve patients’quality of life.This review summarizes the research progress in the roles of EGFR,the treatment strategies and drug resistance in TNBC,in order to provide more reference for treating and improving the prognosis of breast cancer.

作者陈金铭蒋清华陈喆田振振邓亚光宋银宏 CHEN Jinming;JIANG Qinghua;CHEN Zhe;TIAN Zhenzhen;Deng Yaguang;SONG Yinhong(Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy,China Three Gorges University,Yichang 443002,Hubei Province,China;Institute of Infection and Inflammation,China Three Gorges University,Yichang 443002,Hubei Province,China;College of Basic Medical Sciences,China Three Gorges University,Yichang 443002,Hubei Province,China;Research Center for Single Cell Omics and Personalized Medicine(RCSOP),Hwa Mei Hospital,University of Chinese Academy of Sciences,Ningbo 315016,Zhejiang Province,China)

机构地区三峡大学肿瘤微环境与免疫治疗湖北省重点实验室三峡大学感染与炎症损伤研究所三峡大学基础医学院中国科学院大学宁波华美医院个体化医学研究中心

出处《肿瘤》 CAS 北大核心 2023年第10期829-838,共10页 Tumor

关键词三阴性乳腺癌表皮生长因子受体治疗突变耐药 Triple negative breast cancer Epidermal growth factor receptor Treatment Mutation Drug resistance

分类号 R737.9 [医药卫生—肿瘤]

作者简介 Correspondence to:宋银宏,E-mail:syh728@126.com